# Langetermijn ticagrelor monotherapie na 1 maand DAPT bij complexe PCI: GLOBAL LEADERS

*geplaatst 2019-08-14 · Algemeen · European heart journal · doi 10.1093/eurheartj/ehz453 · https://hartvaat.nl/2019/08/14/langetermijn-ticagrelor-monotherapie-na-1-maand-dapt-bij-complexe-pci-global-lea/*

GLOBAL LEADERS subanalyse naar de impact van ticagrelor monotherapie na 1 maand DAPT bij complexe PCI-patiënten.

## English: Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial.

This GLOBAL LEADERS subanalysis evaluated ticagrelor monotherapy after 1 month of DAPT in patients who underwent complex PCI, extending the de-escalation evidence to the highest-complexity interventional subgroup.

## Abstract (original, from the publication)

AIMS: To evaluate the impact of an experimental strategy [23-month ticagrelor monotherapy following 1-month dual antiplatelet therapy (DAPT)] vs. a reference regimen (12-month aspirin monotherapy following 12-month DAPT) after complex percutaneous coronary intervention (PCI). METHODS AND RESULTS: In the present post hoc analysis of the Global Leaders trial, the primary endpoint [composite of all-cause death or new Q-wave myocardial infarction (MI)] at 2 years was assessed in patients with complex PCI, which includes at least one of the following characteristics: multivessel PCI, ≥3 stents implanted, ≥3 lesions treated, bifurcation PCI with ≥2 stents, or total stent length >60 mm. In addition, patient-oriented composite endpoint (POCE) (composite of all-cause death, any stroke, any MI, or any revascularization) and net adverse clinical events (NACE) [composite of POCE or Bleeding Academic Research Consortium (BARC) Type 3 or 5 bleeding] were explored. Among 15 450 patients included in this analysis, 4570 who underwent complex PCI had a higher risk of ischaemic and bleeding events. In patients with complex PCI, the experimental strategy significantly reduced risks of the primary endpoint [hazard ratio (HR): 0.64, 95% confidence interval (CI): 0.48-0.85] and POCE (HR: 0.80, 95% CI: 0.69-0.93), but not in those with non-complex PCI (Pinteraction = 0.015 and 0.017, respectively). The risk of BARC Type 3 or 5 bleeding was comparable (HR: 0.97, 95% CI: 0.67-1.40), resulting in a significant risk reduction in NACE (HR: 0.80, 95% CI: 0.69-0.92; Pinteraction = 0.011). CONCLUSION: Ticagrelor monotherapy following 1-month DAPT could provide a net clinical benefit for patients with complex PCI. However, in view of the overall neutral results of the trial, these findings of a post hoc analysis should be considered as hypothesis generating.

Auteurs: Patrick W Serruys, Kuniaki Takahashi, Ply Chichareon, Norihiro Kogame, Mariusz Tomaniak, Rodrigo Modolo, Chun Chin Chang, Hidenori Komiyama, Osama Soliman, Joanna J Wykrzykowska, Robbert J de Winter, Maurizio Ferrario, Marcello Dominici, Paweł Buszman, Leonardo Bolognese, Carlo Tumscitz, Edouard Benit, Hans-Peter Stoll, Christian Hamm, Philippe Gabriel Steg, Yoshinobu Onuma, Peter Jüni, Stephan Windecker, Pascal Vranckx, Antonio Colombo, Marco Valgimigli

---
Bron: European heart journal, https://doi.org/10.1093/eurheartj/ehz453. Bijgewerkt 2026-07-03T13:27:17Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.